Creative Biolabs Applauds Emory for COVID-19 Antiviral Drug Discovery New Progress

The established biotech company, Creative Biolabs, which is dedicated to therapeutic antibody discovery, drug candidates screening, in vitro diagnostic immunoassay services, and vaccine development service for SARS-CoV-2, extends congratulations to Emory researchers who made extraordinary progress in developing Molnupiravir, the first-ever pill to treat COVID-19 if authorized.

New York, USA – November 2, 2021 – Researchers at Emory University invented the antiviral drug Molnupiravir that targets the viral polymerase, an enzyme that viruses need for replication. This experimental COVID-19 antiviral can introduce errors into the genetic code of the virus, which, if emergency use is approved, could be the first oral antiviral medicine to treat COVID-19. As a life science company functioning for SARS-CoV-2 therapeutics development, Creative Biolabs is delighted to witness this advancement and delivers congratulations by enhancing its series of services in antiviral therapeutic development, including antiviral peptide discovery and neutralizing antibody development, to help other participants in the race of COVID-19 treatment.

Fusion Peptide (Inhibitor) EK1 Development

The receptor binding and the membrane fusion process of SARS-CoV-2 are mediated by the spike (S) membrane glycoprotein, for which the S protein is a crucial breach for the SARS-CoV-2 drug discovery. Peptides from functional HR2 regions in the S protein of SARS-CoV-2 can stop viral fusion and entry into host cells. For instance, the modified OC43-HR2P peptide, EK1, is a pan-CoV viral fusion inhibitor to inhibit human coronavirus infection. Creative Biolabs has elevated the fusion peptide EK1 development services and other antiviral peptide discovery services to encourage SARS-CoV-2 research since the fusion peptide for SARS-CoV-2 shows potential prophylactic and therapeutic effect.

Neutralizing Antibody Development

Neutralizing antibodies (nAbs) can provide protection against SARS-CoV-2 by interfering with the virion binding to receptors, blocking viral entry into host cells, and preventing viral genomes from uncoating in endosomes. Thus, nAbs targeting the S-protein on the surface of SARS-CoV-2 is a promising therapy that can offer passive immunity to diseases. Researchers at Creative Biolabs are dedicated to subjects using CR3022, CD4, and glycoprotein as targets for broad SARS-CoV-2 nAbs discovery.

In Vitro Diagnostic (IVD) Reagent Development for SARS-CoV-2

In addition to the contribution to antiviral drug discovery, Creative Biolabs also offers an advanced SARS-CoV-2 IVD reagent development platform to enhance COVID-19 detection. The platform can assist related research agencies with assays establishment and IVD reagents development for SARS-CoV-2, including antibodies/antigens production for serological testing, immunoassay validation, molecular diagnostic assay development, and kit production.

About Creative Biolabs

Creative Biolabs is the world’s leading custom biotechnology company powering early drug discovery. Serving the entire drug discovery community-pharmaceutical companies, academic institutions, research organizations, and biotechnology companies for decades-Creative Biolabs is committed to aiding scientists in basic drug discovery and novel therapeutics development with high-quality products and services. For more COVID-19 information about therapeutic antibody discovery, antiviral drug candidates screening, and vaccine development, please visit

Media Contact
Company Name: Creative Biolabs
Contact Person: Candy Swift
Email: Send Email
Phone: 1-631-830-6441
Country: United States